Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tedizolid for Orthopedic Device Infections
NCT03378427Completed
- Sponsor
- Centre Hospitalier de Tourcoing
- Start
- Aug 2018
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tedizolid in orthopedic device infection (ODRI), sponsored by Centre Hospitalier de Tourcoing. Primary endpoints: Bone marrow toxicity at 12 months, Peripheral neuropathy at 12 months and 3 more. Started Aug 2018; status: completed.
02
Drugs
tedizolid
03
Conditions
orthopedic device infection (ODRI)
Beyond the preview
Go deeper on NCT03378427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03378427.